A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.
A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP-721 in Healthy Subjects (Part 1) and the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of EDP-721 in Combination With EDP-514 in Patients With Chronic Hepatitis B Virus Infection (Part 2)
Sponsor: Enanta Pharmaceuticals, Inc
Terminated
Due to adverse safety signals in Part 1 (HV)
Other terminated trials from Enanta Pharmaceuticals, Inc
- Respiratory Syncytial Virus Infections · Phase PHASE2 · May 2023
- Non-Alcoholic Steatohepatitis · Phase PHASE2 · Nov 2021
- Healthy · Phase PHASE1 · Oct 2014
More terminations from Enanta Pharmaceuticals, Inc
Listed as NCT04971512, this PHASE1 trial focuses on Chronic Hepatitis B Virus Infection and remains terminated or withdrawn. Sponsored by Enanta Pharmaceuticals, Inc, it has been updated 5 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Mar 2022 — Nov 2022 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2021 — Mar 2022 [monthly]
Recruiting PHASE1
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Enanta Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .